Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial

被引:40
|
作者
de Vries, Kim C. [1 ]
Wortel, Ruud C. [1 ]
Oomen-de Hoop, Esther [1 ,2 ]
Heemsbergen, Wilma D. [1 ]
Pos, Floris J. [3 ]
Incrocci, Luca [1 ]
机构
[1] Erasmus MC, Dept Radiat Oncol, Rotterdam, Netherlands
[2] Erasmus MC, Clin Trial Ctr, Rotterdam, Netherlands
[3] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
关键词
NON-INFERIORITY; PRIMARY TUMOR; RADIOTHERAPY; RECURRENCE; SITE; EFFICACY;
D O I
10.1016/j.ijrobp.2019.09.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In the multicenter, phase 3, HYpofractionated irradiation for PROstate cancer trial, hypofractionated (HF) radiation therapy was compared with conventionally fractionated (CF) radiation therapy. In previous reports, we could not demonstrate the postulated superiority of hypofractionation in terms of relapse-free survival at 5 years. The frequent use of long-term androgen deprivation therapy might have had substantial effects on relapse-free survival. In the current analysis, we provide updated 7-year relapse-free survival outcomes. Methods and Materials: We enrolled patients with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer. Patients were randomly assigned (1:1) to either HF (64.6 Gy in 19 fractions) or CF (78.0 Gy in 39 fractions) radiation therapy. Based on an estimated alpha/beta ratio for prostate cancer of 1.5 Gy, the EQD2 was 90.4 Gy for HF versus 78.0 Gy for CF radiation therapy. The primary endpoint of the present analysis is relapse-free survival at 7 years. Results: A total of 820 patients were enrolled, of whom 804 were assessable for the current evaluation (407 HF versus 397 CF). Median follow-up was 89 months (interquartile range, 83-99). Concomitant androgen deprivation therapy was prescribed for 537 ( 67%) of 804 patients for a median duration of 32 months (interquartile range, 10-44). Treatment failure at 7 years was reported in 220 (27.4%) of 804 patients, 107 ( 26.3%) in HF versus 113 (28.5%) in CF radiation therapy. Seven-year relapse-free survival was 71.7% (95% confidence interval [CI], 66.4-76.4) for HF versus 67.6% ( 95% CI, 62.0-72.5) for CF (P = .52). Overall survival was 80.8% (95% CI, 76.5-84.4) in HF versus 77.6% (95% CI, 73.0-81.5) in CF radiation therapy (P = .17). Conclusions: The current results of 7-year relapse-free survival confirmed our previous findings that the hypothesized dose escalation in the HF arm did not translate to superior tumor control compared with the CF arm. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:108 / 115
页数:8
相关论文
共 50 条
  • [21] Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
    Guo, Wei
    Sun, Yun-Chuan
    Bi, Jian-Qiang
    He, Xin-Ying
    Xiao, Li
    BMC CANCER, 2019, 19 (01)
  • [22] Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
    Mascarenhas, John O.
    Harrison, Claire
    Bose, Prithviraj
    Kiladjian, Jean-Jacques
    Lucchesi, Alessandro
    Vannucchi, Alessandro Maria
    Berry, Tymara
    Riggs, Jennifer
    Peng, Lixian
    Huang, Fei
    Wan, Ying
    Rodolf, Vivian
    Ho, Judy
    Navada, Shyamala
    Komrokji, Rami S.
    BLOOD, 2024, 144 : 18081 - 18083
  • [23] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    C. Ola Landgren
    Ajai Chari
    Yael C. Cohen
    Andrew Spencer
    Peter Voorhees
    Jane A. Estell
    Irwindeep Sandhu
    Matthew W. Jenner
    Catherine Williams
    Michele Cavo
    Niels W. C. J. van de Donk
    Meral Beksac
    Philippe Moreau
    Hartmut Goldschmidt
    Steven Kuppens
    Rajesh Bandekar
    Pamela L. Clemens
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Craig C. Hofmeister
    Leukemia, 2020, 34 : 1840 - 1852
  • [24] Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial
    Zhang, Li
    Mei, Xin
    Hu, Zhigang
    Yu, Bo
    Zhang, Chaoyang
    Li, Yong
    Liu, Kaitai
    Ma, Xuejun
    Ma, Jinli
    Chen, Xingxing
    Meng, Jin
    Shi, Wei
    Wang, Xiaofang
    Mo, Miao
    Shao, Zhimin
    Zhang, Zhen
    Yu, Xiaoli
    Guo, Xiaomao
    Yang, Zhaozhi
    BMC CANCER, 2024, 24 (01)
  • [25] Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial
    Li Zhang
    Xin Mei
    Zhigang Hu
    Bo Yu
    Chaoyang Zhang
    Yong Li
    Kaitai Liu
    Xuejun Ma
    Jinli Ma
    Xingxing Chen
    Jin Meng
    Wei Shi
    Xiaofang Wang
    Miao Mo
    Zhimin Shao
    Zhen Zhang
    Xiaoli Yu
    Xiaomao Guo
    Zhaozhi Yang
    BMC Cancer, 24
  • [26] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Landgren, C. Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter
    Estell, Jane A.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Catherine
    Cavo, Michele
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Kuppens, Steven
    Bandekar, Rajesh
    Clemens, Pamela L.
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Hofmeister, Craig C.
    LEUKEMIA, 2020, 34 (07) : 1840 - 1852
  • [27] Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study
    Hofmeister, Craig C.
    Chari, Ajai
    Cohen, Yael
    Spencer, Andrew
    Voorhees, Peter M.
    Estell, Jane
    Venner, Christopher P.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Cathy
    Cavo, Michele
    Van de Donk, Niels W. C. J.
    Beksac, Meral
    Kuppens, Steven
    Bandekar, Rajesh
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Goldschmidt, Hartmut
    Landgren, Ola
    BLOOD, 2017, 130
  • [28] Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial
    Blanchard, Pierre
    Faivre, Laura
    Lesaunier, Francois
    Salem, Naji
    Mesgouez-Nebout, Nathalie
    Deniau-Alexandre, Elisabeth
    Rolland, Frederic
    Ferrero, Jean-Marc
    Houede, Nadine
    Mourey, Loic
    Theodore, Christine
    Krakowski, Ivan
    Berdah, Jean-Francois
    Baciuchka, Marjorie
    Laguerre, Brigitte
    Davin, Jean-Louis
    Habibian, Muriel
    Culine, Stephane
    Laplanche, Agnes
    Fizazi, Karim
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (01): : 85 - 92
  • [29] Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial
    Roy, Soumyajit
    MacRae, Robert
    Grimes, Scott
    Malone, Julia
    Lock, Michael
    Mehra, Prateek
    Morgan, Scott C.
    Malone, Shawn
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1386 - 1393
  • [30] Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial
    Niazi, T. M.
    Nabid, A.
    Malagon, T.
    Bettahar, R.
    Vincent, L. S.
    Martin, A. G.
    Jolicoeur, M.
    Yassa, M.
    Barkati, M.
    Igidbashian, L.
    Bahoric, B.
    Archambault, R.
    Villeneuve, H.
    Mohiuddin, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S3 - S3